<DOC>
	<DOCNO>NCT00414284</DOCNO>
	<brief_summary>This study look see increase standard dose Kaletra tolerate low viral load undetectable level . This study also look pharmacokinetic data ( amount Kaletra blood different time ) .</brief_summary>
	<brief_title>BOOST : Study Increased Dosage Lopinavir/Ritonavir ( LPV/r )</brief_title>
	<detailed_description>There several reason low level viremia patient Kaletra ( LPV/r ) , include poor adherence , incomplete absorption , cellular drug pump resistance mutation . Increasing exposure protease inhibitor via boost ritonavir increase minimum blood concentration , strategy show improve suppression virologic replication . Little known pharmacokinetics ( PK ) , tolerability safety increase dos LPV/r . The objective 24-week single arm pilot study ass PK parameter , safety , tolerability , change viral load CD4 count increase dose ( 600/150 800/200 mg ) LPV/r participant low level viremia standard dose LPV/r-based ART . Participants undergo six PK sampling 12 hour standard dose LPV/r . The dose increase 3 tab ( 600/150 ) BID blood sample PK two week . If tolerate 8 week , dose increase 4 tab ( 800/200 mg ) BID final PK sampling perform two week . There one time , optional , optimization background regimen NRTIs two week first dose escalation . Major Eligibility Criteria : - CD4 count : &gt; 50 - Viral load : 200-75,000 two recent measure - Current treatment : &gt; 16 week standard dose ( 400/100mg BID ) LPV/r-based ART ( PI NNRTI allow - Prior treatment experience resistance profile : Up 20-fold resistance LPV/r</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>CD4 Count &gt; 50 Viral load 20075,000 two recent measure More 16 week standard dose Kaletra ( LPV/r ) May initial PI regimen prior PI usage Up 50fold resistance LPV/r Age &lt; 18 year old</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>HIV/AIDS</keyword>
	<keyword>viremia</keyword>
	<keyword>Kaletra</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>viral load</keyword>
	<keyword>LPV/r</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>